Management of relapsed/refractory diffuse large B-cell lymphomas in 2020 in Belgium. A 1-year experience with tisa-cel (Kymriah®), the first anti-CD19 CAR-T cell to be reimbursed
Sarah Bailly, Xavier Poiré, Nicole Straetmans, Violaine Havelange, Marie-Christiane Vekemans, Eric Van Den NestePublished in the journal : February 2021Category : Hematology/Oncology
Summary :
Recently, the management of relapsed/refractory diffuse large B-cell lymphoma has been revolutionized by the introduction of of anti-CD19 CAR-T cells. These treatments have been available in Belgium since mid-2019.
What to remember after one year of experience?
Key Words
Relapsed/refractory diffuse large B-cell lymphoma, anti-CD19 CAR-T cells